• AZD2461: Novel PARP Inhibitor Redefining Breast Cancer Re...

  2026-03-21

  AZD2461 stands out as a next-generation poly (ADP-ribose) polymerase inhibitor, combining potent cytotoxicity in breast cancer models with the unique ability to bypass Pgp-mediated drug resistance. Its robust in vitro and in vivo performance, coupled with optimized workflows, empowers researchers to dissect DNA repair pathways and develop advanced strategies for overcoming therapeutic resistance.

• Fluorescent Cell Viability Assays in the Era of Precision...

  2026-03-20

  Translational researchers face mounting pressure to generate reliable, mechanistically insightful data on cell viability, inflammation, and apoptosis—cornerstones of disease modeling and drug discovery. This thought-leadership article synthesizes foundational principles of membrane integrity assays, highlights transformative evidence from recent disease research, and delivers actionable guidance on deploying AO/PI Staining Solution from APExBIO for next-generation fluorescence-based cell counting and viability assays. The discussion advances beyond conventional product pages by integrating mechanistic insight, critical evaluation of assay technologies, and a forward-looking perspective on translational utility.

• (S)-(+)-Dimethindene maleate: Selective M2 Muscarinic Rec...

  2026-03-20

  (S)-(+)-Dimethindene maleate is a rigorously selective M2 muscarinic receptor antagonist and histamine H1 receptor antagonist, enabling precise dissection of autonomic regulation, cardiovascular, and respiratory pathways. As a research tool from APExBIO, it provides benchmark selectivity and reproducibility for pharmacological studies targeting muscarinic and histaminergic signaling.

• Scenario-Based Best Practices with AO/PI Staining Solutio...

  2026-03-19

  This article provides biomedical researchers and lab technicians with an in-depth, scenario-driven guide for employing AO/PI Staining Solution (SKU K2269) in cell viability and cytotoxicity assays. Drawing on laboratory challenges and current literature, it demonstrates how dual acridine orange/propidium iodide staining delivers reproducible, interference-free results for live/dead cell discrimination and accurate cell counting.

• AO/PI Staining Solution: Accurate Fluorescent Live/Dead C...

  2026-03-19

  AO/PI Staining Solution is a robust fluorescent cell viability assay reagent that enables precise live/dead cell discrimination using acridine orange and propidium iodide. It delivers superior accuracy over trypan blue in fluorescence-based cell counting and is validated for cytotoxicity research requiring uncompromised cell membrane integrity assessment.

• BMN 673: Potent PARP1/2 Inhibitor for Homologous Recombin...

  2026-03-18

  BMN 673 (Talazoparib) stands out as a selective PARP1/2 inhibitor, designed to exploit DNA repair vulnerabilities in cancer cells, especially those deficient in homologous recombination. Its superior PARP-DNA complex trapping and nanomolar potency empower researchers to achieve high assay sensitivity and translational relevance in both in vitro and in vivo models.

• Olaparib (AZD2281): Selective PARP-1/2 Inhibitor Empoweri...

  2026-03-18

  Olaparib (AZD2281) stands out as a transformative selective PARP-1/2 inhibitor, enabling targeted DNA damage response assays and advanced tumor radiosensitization studies—especially in BRCA-deficient models. This guide delivers actionable protocols, troubleshooting strategies, and future-oriented insights to maximize the impact of Olaparib in translational cancer research.

• AO/PI Staining Solution: Advanced Live/Dead Cell Discrimi...

  2026-03-17

  Discover how AO/PI Staining Solution empowers fluorescence-based cell counting and mechanistic research in cell viability and apoptosis. This in-depth guide highlights its unique value for precise live dead cell discrimination and advanced cellular pathway analysis.

• Olaparib (AZD2281): Mechanistic Insights and Emerging Fro...

  2026-03-17

  Explore the advanced mechanism and research applications of Olaparib (AZD2281), a leading PARP-1/2 inhibitor for BRCA-deficient cancer research. This article provides new scientific perspectives, integrating recent findings on platinum resistance and DNA repair, to guide innovative experimental design.

• AZD0156: Potent and Selective ATM Kinase Inhibitor for Ca...

  2026-03-16

  AZD0156 is a potent, selective ATM kinase inhibitor developed for cancer research. This compound demonstrates sub-nanomolar efficacy and over 1,000-fold selectivity for ATM versus other PIKK kinases, enabling precise modulation of DNA damage response pathways. Recent studies confirm its utility in uncovering metabolic vulnerabilities in cancer cells, making it a critical tool for DNA damage response and checkpoint control research.

• Plerixafor (AMD3100): CXCR4 Chemokine Receptor Antagonist...

  2026-03-16

  Plerixafor (AMD3100) is a potent CXCR4 chemokine receptor antagonist widely used for cancer metastasis inhibition and hematopoietic stem cell mobilization studies. Its high specificity and reproducible activity make it a gold standard in SDF-1/CXCR4 axis research. This article details its biological rationale, mechanisms, comparative evidence, and practical integration for research workflows.

• AZD2461: Novel PARP Inhibitor for Breast Cancer Research ...

  2026-03-15

  AZD2461 is a novel poly (ADP-ribose) polymerase inhibitor (PARPi) with potent PARP-1 inhibition, low P-glycoprotein affinity, and demonstrated efficacy in breast cancer models. This article summarizes key mechanisms, evidence, and best practices for deploying AZD2461 in translational oncology research.

• 17-AAG (Tanespimycin): Systems Biology Insights into HSP9...

  2026-03-14

  Explore the multifaceted mechanism of 17-AAG, a leading HSP90 inhibitor, in cancer biology. This article uniquely bridges synthetic geldanamycin analogues, chaperone disruption, and regulated cell death pathways—delivering advanced insights for translational researchers.

• Plerixafor (AMD3100): A CXCR4 Chemokine Receptor Antagoni...

  2026-03-13

  Plerixafor (AMD3100) is a potent CXCR4 chemokine receptor antagonist used in cancer research and hematopoietic stem cell mobilization studies. It disrupts the CXCL12/CXCR4 axis, inhibiting metastasis and increasing circulating stem and immune cells in validated model systems. APExBIO’s Plerixafor is a benchmark tool for dissecting CXCR4-mediated pathways.

• 3-Deazaadenosine: Mechanisms, Epigenetic Impact, and Tran...

  2026-03-13

  Discover how 3-Deazaadenosine, a potent S-adenosylhomocysteine hydrolase inhibitor, advances methylation research and preclinical antiviral models. This article uniquely explores its mechanistic role in epigenetic regulation and translational applications beyond conventional workflows.

11336 records 1/756 page Next 12345 下5页 Last page